Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia

Pathologie Biologie

Volumn 57, Issue 5, 2009, Pages 388-391

  Menif, S ^a   Zarrouki, S ^a   Jeddi, R ^b   Alaya, N ben ^a,b,c,d   Ali, Z BelHadj ^b   Abid, H Ben ^b   Hdeiji, S ^d   Elloumi, M ^d   Khlif, A ^c   Meddeb, B ^b   Dellagi, K ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^b Hopital Aziza Othmana   (Tunisia)

^c FARHAT HACHED HOSPITAL   (Tunisia)

^d HEDI CHAKER HOSPITAL   (Tunisia)

Author keywords

Chronic myeloid leukemia; Imatinib; PCR; Residual disease; RQ

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB; RNA;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; DNA SYNTHESIS; FEMALE; FOLLOW UP; HUMAN; MALE; MONITORING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUNISIA;

ADULT; ANTINEOPLASTIC AGENTS; COMPUTER SYSTEMS; FEMALE; FOLLOW-UP STUDIES; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; NEOPLASM, RESIDUAL; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RNA, MESSENGER; RNA, NEOPLASM; TUMOR BURDEN; TUNISIA;

EID: 67649200402     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2007.12.010     Document Type: Article

References (18)

1. Melo J.V. The diversity of bcr-abl fusion proteins and their relationship to leukemia phenotype. Blood 88 (1996) 2375-2384
2. Cross N., melo J.V., and feng L. An optimized multiplex polymerase chain for detection of bcr-abl fusion mRNA in haematological disorders. Leukemia 8 (1994) 186-189
3. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344 (2001) 1031-1037
4. Emig M., Saussele S., Wittor H., et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 13 (1999) 1825-1832
5. Braziel R.M., Launder T.M., Druker B.J., et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients:14 months'experience. Blood 100 (2002) 435-441
6. Baccarani M., Saglio G., and Goldman J. Evolving concepts in the management of chronic myeloid leukaemia. Recommandations from an expert panel on behalf of the European Leukemianet. Blood (2006)
7. Gabert J., Beillard E., and Van der velden. Standardization and quality control studies of real time quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia. a Europe Against cancer program. Leukemia 17 (2003) 2318-2357
8. Kantarjian H., Sawyers C., hochhaus A., et al. Hematologic and cytogenetic responses to to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346 (2002) 645-652
9. Kantarjian H.M., Cortes J.E., O'Brien S., et al. Imatinib mesylate therapy in newly diagnosed patients with philadelphia chromosome positive chronic incidence of early complete and major cytogenetic responses. Blood 101 (2003) 97-100
10. Hughes T.P., Kaeda J., Brandford S., Rudzki Z., et al. Frequency of major molecular responses to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
11. Muller M.C., Gattermann N., Lahaye T., et al. Dynamics of bcr-abl mRNA expression in first line therapy of chronic myelogenous leukemia patients with imatinb or interferon alpha/araC. Leukemia 17 (2003) 2392-2400
12. Brandford S., Hughes T.P., and Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol 107 (1999) 587-599
13. Kaeda J., Chase A., and Goldman J.M. Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukemia. Acta Haematol 107 (2002) 64-75
14. Stentoft J., Pallisgaard N., Jeldsen K., et al. Kinetics of bcr-abl fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real time polymerase chain reaction. Eur J Haematol 67 (2001) 302-308
15. Kantarjian H.M., Talpaz M., Cortes J., et al. Quantitative polymerase chain reaction monitoring of bcr-abl during therapy with imatinib mesylate(STI 571) in chronic phase chronic myelogenous leukaemia. Clin cancer Reseach 9 (2003) 160-166
16. Merx K., Muller M.C., Kreil S., et al. Early m RNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 16 (2002) 1579-1583
17. Wang L., Pearson K., and Pilliteri L. Serial monitoring of bcr-abl by peripheral blood real time polymerase chain reaction predicts the marrow cytogenetic response to imatinb mesylate in chronic myeloid leukaemia. Br J Haematol 118 (2002) 771-777
18. Iacobucci I., Saglio G., Rosti G., et al. Achieving a major molecular response at the time of a complete cytogenetic response predicts a better duration of CCR in imatinib treated chronic myeloid leukemia patients. Clin cancer Research (2006)